English | 简体中文 | 繁體中文 | 한국어
Share:
ObsEva SA to Host Key Opinion Leader Meeting on In Vitro Fertilization (IVF) April 26, 2018 in New York City

ObsEva SA / ObsEva SA to Host Key Opinion Leader Meeting on In Vitro Fertilization (IVF) April 26, 2018 in New York City . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement.

Geneva, Switzerland and Boston, MA - April 16, 2018- ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy, today announced that the company will host a key opinion leader (KOL) meeting focused on in vitro fertilization (IVF) Thursday, April 26 from 12:00 to 2:00 p.m. ET in New York City. 

The meeting will feature presentations from David Seifer, M.D., Professor of Obstetrics, Gynecology and Reproductive Sciences, Yale School of Medicine, and Annette Lee M.D., Medical Director, Toll Center for Reproductive Sciences, Abington Reproductive Medicine. Additionally, members of the ObsEva management team will provide an overview of the company's oral oxytocin receptor antagonist nolasiban, including recently released positive top line results from the Phase 3 IMPLANT2 clinical trial.

A live webcast of the meeting will be accessible under the "Investors" section of ObsEva's website www.obseva.com.

About ObsEva

ObsEva is a clinical-stage biopharmaceutical company focused on the clinical development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids, preterm labor and improving IVF outcomes. ObsEva is listed on The NASDAQ Global Select Market and is trading under the ticker symbol "OBSV". For more information, please visit www.ObsEva.com.

###

Media Contact:
Liz Bryan
Spectrum Science
lbryan@spectrumscience.com
202-955-6222 x2526

CEO Office Contact:
Shauna Dillon
Shauna.dillon@obseva.ch
+41 22 552 1550

Investor Contact:
Mario Corso
Senior Director, Investor Relations
mario.corso@obseva.com
857-972-9347 office
781-366-5726 mobile




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: ObsEva SA via Globenewswire

Copyright © Thomson Reuters 2018. All rights reserved.
Press Releases
Orion to sell its Orion Diagnostica division - Due to the transaction Orion updates its outlook  
Apr 21, 2018 00:30 ET
Helsinn Group announces the FDA approval of the IV formulation of AKYNZEO® (fosnetupitant/ palonosetron) in the United States  
Apr 20, 2018 21:33 ET
BOURBON: Positive progress in negotiations with lenders  
Apr 20, 2018 18:30 ET
Hubbell Incorporated Declares Regular Quarterly Dividend  
Apr 20, 2018 16:01 ET
Helsinn Group announces the FDA approval of the IV formulation of AKYNZEO® (fosnetupitant/ palonosetron) in the United States  
Apr 20, 2018 15:23 ET
Heineken Holding N.V. - Amendments to the Articles of Association  
Apr 20, 2018 15:18 ET
Lubrizol Presents Estane® TPU and Other Innovations for Consumer, Industrial, Footwear and Electronics Applications at Chinaplas 2018  
Apr 20, 2018 12:03 ET
Lipotec Active Ingredients Becomes Umbrella Brand  
Apr 19, 2018 23:43 ET
LEH PHARMA LTD.: Company Update  
Apr 18, 2018 19:34 ET
Tusk Therapeutics presents data on to its anti-CD25 programme at AACR Annual Meeting 2018  
Apr 18, 2018 19:33 ET
More News >>
Copyright © 2018 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 5791 1818

Connect With us: